Lantheus Holdings, Inc. · NASDAQ:LNTH
Lantheus — Q1 2026 Earnings Presentation
27 slides from Lantheus's earnings presentation, May 7, 2026
Slide 1: Lantheus First Quarter 2026 Results
Lantheus First Quarter 2026 Results MAY 7, 2026 © 2026 Lantheus. All rights reserved.
Slide 2: Agenda
Agenda SPEAKERS Highlights & Business Update Commercial Update Financial Update Mary Anne Heino Amanda Morgan Bob Marshall Mark Kinarney Vice President, Executive Board Chair Chief Commercial CFO and & CEO Officer Treasurer Investor Relations Closing Remarks Q&A © 2026 Lantheus. All rights reserved.
Slide 3: Safe Harbor Statements
Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe har
Slide 4: Agenda
Agenda SPEAKERS Highlights & Business Update Commercial Update Financial Update Mary Anne Heino Amanda Morgan Bob Marshall Mark Kinarney Vice President, Executive Board Chair Chief Commercial CFO and & CEO Officer Treasurer Investor Relations Closing Remarks Q&A © 2026 Lantheus. All rights reserved.
Slide 5: Lantheus, the Leading Radiopharmaceutical-focused Company
Lantheus, the Leading Radiopharmaceutical-focused Company STRONG START TO 2026 2026: A Year of Commercial Execution and Regulatory Milestones $240.9M Maintain our market leadership BUILD MOMENTUM 1Q 2026 Revenue 1 in PSMA PET 2 for Neuarceq Market-leading PSMA PET imaging agent1 Through deeper penet
Slide 6: Positioning Lantheus for the Next Phase of Leadership & Growth
Positioning Lantheus for the Next Phase of Leadership & Growth In addition to strong commercial execution, we advanced several important programs: PYLARIFY TruVu OCTEVY PNT2003 FDA APPROVED PDUFA DATE EXTENDED FDA TENTATIVE APPROVAL March 6 June 29 March 2 PYLARIFY TruVu offers the same PDUFA date e
Slide 7: Building the Next Wave of PET Diagnostics
Building the Next Wave of PET Diagnostics Diagnostic Therapeutic Candidate Target Isotope Indication/Disease Area Pre-Clinical Phase 1 Phase 2 Phase 3 Reg. Filing Prostate Cancer LNTH-24011 GRPR 68Ga Metastatic Prostate Cancer Neuroendocrine Tumors LNTH-2501/EVG0012 SSTR2 68Ga NETs LNTH-1363S FAP 64
Slide 8: Agenda
Agenda SPEAKERS Highlights & Business Update Commercial Update Amanda Morgan Morgan Financial Update Mary Anne Heino Amanda Chief Commercial Chief Commercial Bob Marshall CFO and Mark Kinarney Vice President, Executive Board Chair & CEO Officer Officer Treasurer Investor Relations Closing Remarks Q&
Slide 9: $240.9M +5.8% Volume Growth
Utilized PSMA PET Imaging Agent1 1Q 2026 $240.9M +5.8% Volume Net Sales Growth Year-over-Year • Performance driven by: • consistent demand across our established customer base • continued pricing discipline in a highly competitive environment • Net ASP and volume remained stable sequentially 1. Inte
Slide 10: PYLARIFY TruVu: Next Chapter of our PSMA PET Portfolio
PYLARIFY TruVu: Next Chapter of our PSMA PET Portfolio NOW APPROVED REIMBURSEMENT & REGULATORY PATHWAY • HCPCS code application submitted • Filing planned for transitional pass-through status • Coordinating with PMF partners to secure FDA manufacturing site approvals ahead of initiating regional con
Slide 11: $35.4M +14.3% sequential
Fastest Growing Most Beta-amyloid Utilized1 in PET Agent1 the U.S. 1Q 2026 $35.4M +14.3% sequential growth vs. 4Q 2025 Net Sales Revenue growth Expanded driven by increased manufacturing utilization within footprint existing accounts Leveraging existing Ongoing adoption of nuclear medicine Alzheimer
Slide 12: $84.6M +6.8% Growth
Utilized Ultrasound Enhancing Agent1,2 1Q 2026 $84.6M +6.8% Growth Net Sales Year-over-Year Driven by increased >80% volume demand Market Share Durable, Long-standing Franchise and Consistent Utilization Across Care Settings 25 YEARS 1. DRG Real World Data (RWD) report; 2. Internal analyses and data
Slide 13: Agenda
Agenda SPEAKERS Highlights & Business Update Commercial Update Financial Update Mary Anne Heino Amanda Morgan Bob Marshall Mark Kinarney Vice President, Executive Board Chair Chief Commercial CFO and & CEO Officer Treasurer Investor Relations Closing Remarks Q&A © 2026 Lantheus. All rights reserved.
Slide 14: 1Q 2026 Financial Results
1Q 2026 Financial Results1 1Q 2026 vs. 1Q 2025 1Q 2026 vs. 1Q 2025 $377.3 GAAP EPS $1.80 +76.5% Net Revenues +1.2% Million Non-GAAP EPS $1.462 -4.6% Oncology Cardiology $240.9M $84.6M -6.5% YoY +6.8% YoY Neurology Strategic $35.4M Partnerships $16.3M +52.1% YoY Focus on Driving Commercial Execution
Slide 15: Strong Capital Resources Provide Financial Flexibility
Strong Capital Resources Provide Financial Flexibility1 Cash Flow Summary Free Cash Flow2 Resources USD Millions USD Millions (1Q 2026) Three Months Ending March 31 +$23.1 INCREASE 2025 2026 $498.6M Cash provided $107.6 $125.1 CASH ON HAND3 by operations Cash (used in) $121.9 provided by ($63.7) $26
Slide 16: Reaffirmed FY 2026 Corporate Financial Guidance
Reaffirmed FY 2026 Corporate Financial Guidance1 Issued May 7, 2026 The Company guidance for the full year 2026 is as follows: Revenue $1.4B – $1.45B FY 2026 2 Adjusted Fully Diluted EPS $5.00 – $5.25 1. On a forward-looking basis, the Company does not provide GAAP income per common share guidance o
Slide 17: Agenda
Agenda SPEAKERS Highlights & Business Update Commercial Update Financial Update Mary Anne Heino Amanda Morgan Bob Marshall Mark Kinarney Vice President, Executive Board Chair Chief Commercial CFO and & CEO Officer Treasurer Investor Relations Closing Remarks Q&A © 2026 Lantheus. All rights reserved.
Slide 18: Lantheus, the Leading Radiopharmaceutical-focused Company
Lantheus, the Leading Radiopharmaceutical-focused Company Strong Execution ACROSS ENTIRE PORTFOLIO REGULATORY MILESTONES ACHIEVED 1Q 2026 Revenue FDA $240.9M Approval Market-leading PSMA PET imaging agent1 Reinforces our ability to serve the PSMA PET market reliably and at scale $35.4M Second-larges
Slide 19: Agenda
Agenda SPEAKERS Highlights & Business Update Commercial Update Financial Update Mary Anne Heino Bob Marshall Amanda Morgan Mark Kinarney Vice President, Executive Board Chair CFO and Chief Commercial & CEO Treasurer Officer Investor Relations Closing Remarks Q&A © 2026 Lantheus. All rights reserved.
Slide 20: Appendix
Appendix © 2026 Lantheus. All rights reserved. 20
Slide 21: Condensed Consolidated Statement of Operations – 1Q 2026
Condensed Consolidated Statement of Operations – 1Q 2026 © 2026 Lantheus. All rights reserved. 21
Slide 22: As Adjusted Condensed Consolidated Statement of Operations – 1Q 2026
As Adjusted Condensed Consolidated Statement of Operations – 1Q 2026 © 2026 Lantheus. All rights reserved. 22
Slide 23: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share and percent data - unaudited) (a) Represents the estimated income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP). (b) Amounts may not add due to rounding. © 2026 Lantheus.
Slide 24: Consolidated Statement of Operations
Consolidated Statement of Operations (in thousands, except per share data - unaudited) © 2026 Lantheus. All rights reserved. 24
Slide 25: Consolidated Segment Revenues Analysis
Consolidated Segment Revenues Analysis (in thousands - unaudited) © 2026 Lantheus. All rights reserved. 25
Slide 26: Reconciliation of Free Cash Flow
Reconciliation of Free Cash Flow (in thousands - unaudited) © 2026 Lantheus. All rights reserved. 26
Slide 27: Condensed Consolidated Balance Sheet
Condensed Consolidated Balance Sheet (in thousands - unaudited) © 2026 Lantheus. All rights reserved. 27